#United States #Robbins Geller #San Diego #Rocket Pharmaceuticals #RCKT

Update on Rocket Pharmaceuticals Class Action Lawsuit

Investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have the opportunity to become lead plaintiffs in a class action lawsuit following serious allegations against the company. The law firm Robbins Geller Rudman & Dowd LLP has announced that individuals who purchased or acquired RCKT securities between February 27, 2025, and May 26, 2025, are encouraged to join the lawsuit and represent fellow investors who have suffered significant financial losses.

Background of the Case

The lawsuit, officially titled Ho v. Rocket Pharmaceuticals, Inc., alleges that Rocket Pharmaceuticals and its executives violated the Securities Exchange Act of 1934 by providing misleading information concerning their clinical trials. Specifically, the case points to the company's Phase 2 pivotal trial of a gene therapy, RP-A501, aimed at treating a serious condition known as Danon disease.

During the Class Period, investors were reportedly not informed about serious adverse events occurring during the trial, including patient fatalities associated with the treatment. The protocol for the clinical trial was modified to introduce a novel immunomodulatory agent, a critical detail that was not disclosed to investors at the time, according to the lawsuit's filings.

What Happened?

On May 27, 2025, an announcement was made by Rocket Pharmaceuticals stating that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on their RP-A501 Phase 2 pivotal study. This hold was due to at least one serious adverse event, which unfortunately led to a patient's death, related to the treatment regimen that had recently been altered without informing investors. Following this announcement, Rocket Pharmaceuticals’ stock prices experienced a significant decline, causing distress among investors who now face substantial losses.

Participation in the Lawsuit

The law firm Robbins Geller is calling on affected investors to file for lead plaintiff appointment by August 11, 2025. The Private Securities Litigation Reform Act allows any investor from the class period to seek this position, and the individual with the most significant financial stake, who can adequately represent the group, will be selected.

Becoming a lead plaintiff provides an opportunity to guide the lawsuit on behalf of all involved parties, allowing the individual to choose a law firm to handle the litigation. However, it is important to note that participating as a lead plaintiff is not a prerequisite for receiving any recovery from the eventual settlements or outcomes of the case.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation. They are known for aggressively pursuing compensation for investors, having handled numerous significant cases and achieved remarkable settlements in the past. In 2024 alone, the firm recovered over $2.5 billion for investors through various securities-related class action lawsuits.

To gather more information or to determine eligibility in leading the class action, investors can contact J.C. Sanchez or Jennifer N. Caringal from the law firm via phone or email. More details are also available on their official website.

Conclusion

This is a crucial moment for Rocket Pharmaceuticals investors. If you believe you have been affected by the recent developments regarding RP-A501 and its clinical trials, now is the time to take action. Join others in pursuing justice for any financial losses incurred due to the alleged misinformation provided by the company.

For more information, prospective lead plaintiffs can visit Robbins Geller's website or contact their offices directly.

Stay informed and take control of your investment future by getting involved in this significant case.